135 related articles for article (PubMed ID: 20948453)
21. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
Miller MA; Meschievitz CK; Ballanco GA; Daum RS
Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
[TBL] [Abstract][Full Text] [Related]
22. Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.
Perry CM
Drugs; 2013 May; 73(7):703-13. PubMed ID: 23649970
[TBL] [Abstract][Full Text] [Related]
23. Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers.
Booy R; Nolan T; Reynolds G; Richmond P; Nissen M; Marshall H; Stoney T; Van Der Wielen M; Kolhe D; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):1379-84. PubMed ID: 26372451
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
Halperin SA; King J; Law B; Mills E; Willems P
Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials.
Bryant K; McVernon J; Marchant C; Nolan T; Marshall G; Richmond P; Marshall H; Nissen M; Lambert S; Aris E; Mesaros N; Miller J
Hum Vaccin Immunother; 2012 Aug; 8(8):1036-41. PubMed ID: 22617844
[TBL] [Abstract][Full Text] [Related]
26. An open-label, single-arm, phase I study to evaluate the safety and immunogenicity of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, in healthy adult volunteers.
Kim N; Choi G; Lim CY; Lee JW; Kim KH; Lee HJ
Arch Pharm Res; 2010 Jun; 33(6):919-24. PubMed ID: 20607497
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
Diaz-Mitoma F; Halperin SA; Tapiero B; Hoffenbach A; Zappacosta PS; Radley D; Bradshaw S; Martin JC; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
Vaccine; 2011 Feb; 29(6):1324-31. PubMed ID: 21134456
[TBL] [Abstract][Full Text] [Related]
28. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants.
Bryant KA; Marshall GS; Marchant CD; Pavia-Ruiz N; Nolan T; Rinderknecht S; Blatter M; Aris E; Lestrate P; Boutriau D; Friedland LR; Miller JM
Pediatrics; 2011 Jun; 127(6):e1375-85. PubMed ID: 21624883
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization.
Li G; Zhang H; Zhou W; Ye Q; Li F; Wang H; Hou Q; Xu Y; Ma X; Tan Y; Wang L; Li Y; Li H; Meng F; Liang Q; Liu A; Qin C; Wei W; Liu J; Ruan C; Tao W; Zhang S; Zheng H; Zhu F
Vaccine; 2010 Jun; 28(25):4215-23. PubMed ID: 20399240
[TBL] [Abstract][Full Text] [Related]
32. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Dashefsky B; Wald E; Guerra N; Byers C
Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
[TBL] [Abstract][Full Text] [Related]
33. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of Haemophilus influenzae type B vaccine given in combination with DTwP at 6, 10 and 14 weeks of age.
Cherian T; Thomas N; Raghupathy P; Durot I; Dutta A
Indian Pediatr; 2002 May; 39(5):427-36. PubMed ID: 12037271
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and thermal stability of a combined vaccine against Haemophilus influenzae type b and Neisseria meningitidis serogroup C diseases.
Saydam M; Burkin K; Care R; Rigsby P; Bolgiano B; Mawas F
Vaccine; 2010 Aug; 28(38):6228-34. PubMed ID: 20638457
[TBL] [Abstract][Full Text] [Related]
37. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
38. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
[TBL] [Abstract][Full Text] [Related]
40. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination.
Goldblatt D; Richmond P; Millard E; Thornton C; Miller E
J Infect Dis; 1999 Aug; 180(2):538-41. PubMed ID: 10395878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
